


## HS38

<b>Cat. No.:</b>	HY-15847		
<b>CAS No.:</b>	1030203-81-6		
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>12</sub> ClN <sub>5</sub> O <sub>2</sub> S		
<b>Molecular Weight:</b>	349.8		
<b>Target:</b>	DAPK		
<b>Pathway:</b>	Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 7.14 mg/mL (20.41 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.8588 mL	14.2939 mL	28.5878 mL
5 mM	0.5718 mL	2.8588 mL	5.7176 mL
10 mM	0.2859 mL	1.4294 mL	2.8588 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with K<sub>d</sub>s of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC<sub>50</sub> of 200 nM. HS38 can be used for the research of smooth muscle related disorders<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Kd: 300 nM (DAPK1), 79 nM (DAPK2), 280 nM (ZIPK), IC50: 200 nM (DAPK1), 200 nM (PIM3)<sup>[1]</sup>

#### In Vitro

HS38 displays high affinity toward DAPK2, with a K<sub>d</sub> of 79 nM. DAPK2 is not implicated in smooth muscle contractility<sup>[1]</sup>. HS38 significantly reduces relative RLC20 phosphorylation in both the basal and sphingosine 1-phosphate (S1P) activated states in human aortic SM cells<sup>[1]</sup>.

HS38 reduces contractile forces generated by intact mouse aorta in aortic tissue<sup>[1]</sup>.

HS38 reduces the contractile force, RLC20 phosphorylation, and MYPT1 phosphorylation in Ca<sup>2+</sup>-sensitized rabbit ileum<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

Cell Line:	CA-VSMCs
Concentration:	10 $\mu$ M
Incubation Time:	40 minutes
Result:	Reduced relative RLC20 phosphorylation in both the basal and S1P activated states.

## CUSTOMER VALIDATION

- Life Sci. 2023 Apr 1;121653.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. David A Carlson, et al. Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor. ACS Chem Biol. 2013 Dec 20; 8(12): 2715–2723.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA